Dr Meghan McIlwain, Clinical Research Manager
President, The New Zealand Association of Clinical Research,
AUCKLAND, NEW ZEALAND
Bench Side Story continues with a Clinical Research Manager, and President of New Zealand Association of Clinical Research based in Auckland, NEW ZEALAND.
Dr Meghan McIlwain is a Clinical Research Manager, the President of the New Zealand Association of Clinical Research, a pharmacist and a guest lecturer at the University of Auckland School of Pharmacy. Through her career she’s been a hospital pharmacist, a community pharmacist, a postgraduate student, a postdoctoral researcher, a lecturer and an independent research consultant. Her PhD in is Pharmacy; specifically neuropsychopharmacology.
You Might also like
-
Elite athlete physical and mental health impact performance
Understanding the interaction between genes and lifestyle factors in response to stress can lead to potential therapeutic interventions for stress-related disorders. This research is crucial for promoting health and well-being.
Professor Mehta has recently commenced research into elite athlete physical and mental health impact performance, with research at the intersection of statistics, genomics, and mental health. This research is ahead of, and in anticipation of, the Summer Olympics in Brisbane in 2032.
-
Investigating invasive lobular carcinoma and metaplastic breast cancer sub-types
Assoc Prof McCart Reed is the scientific lead on an MRFF-funded (Medical Research Future Fund) genomics program investigating the potential for the application of Whole Genome Sequencing in the breast cancer care pathway in Australia, ‘Q-IMPROvE’. She applies genomics and spatial transcriptomics methodologies to archival clinical samples to understand the differences between tumour types and their potential for treatment. Amy is passionate about clinical research, biobanking and precision oncology. In addition to her breast cancer research portfolio, she is on the steering committee for the Brisbane Breast Bank and the Scientific Advisory Board for Breast Cancer Trials.
-
Next-generation NK cell-based immunotherapies for hard-to-treat cancers
Associate Professor Fernando Guimaraes is an internationally recognised leader in cancer immunotherapy and natural killer (NK) cell biology. Based at The University of Queensland, he leads innovative research focused on developing next-generation NK cell-based immunotherapies for hard-to-treat cancers, including sarcomas and neuroblastoma.